AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2563
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).

This investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-group study enrolled 74 patients. Eligible patients were randomly assigned to either the edoxaban or warfarin group in a 1:1 ratio. The primary efficacy endpoint was the change in catheter-based PVR at 1 year compared to baseline, with secondary endpoints including clinical worsening of CTEPH, 6-minute walk distance, WHO functional class, and N-terminal pro-brain natriuretic peptide at 1 year. The trial was conducted in eight Japanese institutes within their cardiovascular and pulmonology medicine departments.

Findings demonstrated that edoxaban was noninferior to warfarin in preventing worsening of pulmonary hemodynamics in CTEPH patients who had undergone reperfusion treatment during the 48 weeks treatment. Symptomatic venous thromboembolism and clinically relevant bleeding events were shown to be as low as wafarin
 

Questions

  1. What is the prevalence of chronic thromboembolic pulmonary hypertension (CTEPH), and what is the importance of the KABUKI trial?
  2. What is the existing evidence for the use of DOACs in CTEPH?
  3. What is the study design, and what are the baseline characteristics of the randomized patients?
  4. What are the findings?
  5. Were there any unexpected or surprising findings in the trial?
  6. What are the take-home messages for practice? How widely can the study's findings be applied on a global scale?

Support: This is an independent interview conducted by Radcliffe Cardiology.

Recorded on-site at AHA 2023, Philadelphia

Editors: Mirjam Boros, Jordan Rance
Video Specialists: Mike Knight, Dan Brent

Faculty Biographies

Kazuya Hosokawa

View full profile

Abe Kotaro

View full profile

Comments

You must be to comment. If you are not registered, you can register here.